Gust, Ronald and Beck, Wolfgang and Jaouen, Gerard and Schönenberger, Helmut (2009) Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases Part.2 Use of non-steroidal ligands. Coordination chemistry reviews 253 (21-22), pp. 2760-2779.
Full text not available from this repository.
A review. Platinum complexes with carrier ligands were synthesized to overcome intrinsic and acquired resistance of the tumors during the therapy. For the treatment of breast and prostate cancer steroidal and non-steroidal ligands are available. This article is a crit. review of the attempts made during the last 3 decades to design platinum complexes with a selective mode of action against hormone-dependent tumors. In part 1 of this paper the use of steroidal carrier ligands is described while in part 2 the view is focussed on derivs. of non-steroidal drugs suitable to coordinate to platinum. Esp. the [1,2-diarylethylenediamine]platinum(II) complexes are interesting analogous of cisplatin.
|Additional information (public):||CAN 151:519962 1-0 Pharmacology 15663-27-1 (Cisplatin) Role: PAC (Pharmacological activity), PEP (Physical, engineering or chemical process), THU (Therapeutic use), BIOL (Biological study), PROC (Process), USES (Uses) (complex; optimization of cisplatin for treatment of hormone-dependent tumoral diseases)|
|Institutions:||Chemistry and Pharmacy > Institute of Pharmacy > Retired Professors > Prof. Schönenberger|
|Keywords:||Antitumor agent resistance Antitumor agent resistance Drug design Mammary gland Prostate gland (optimization of cisplatin for treatment of hormone-dependent tumoral diseases) review cisplatin complex hormone dependent tumor antitumor resistance|
|Subjects:||500 Science > 540 Chemistry & allied sciences|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited On:||09 Nov 2010 12:59|
|Last Modified:||12 Nov 2010 06:27|